By
Trending Posts
U.S. FDA Approves JASCAYD® for Progressive Pulmonary Fibrosis…
Boehringer Ingelheim announced that the U.S. Food and Drug Administration (FDA) has approved JASCAYD® (nerandomilast) tablets for the…
Are Galux and Boehringer Ingelheim Pioneering AI in…
December 17, 2025 — Galux, a South Korean biotech company focused on AI-driven protein therapeutics, has entered a…
Has the FDA Approval of Breyanzi Expanded CAR…
Bristol Myers Squibb has received approval from the U.S. Food and Drug Administration for Breyanzi, a CD19-directed CAR…
Does a New Kidney Cancer Trial Expand Long-Term…
December 2025 — Bristol-Myers Squibb and BioNTech have announced progress in their oncology collaboration with the initiation of…
Is Gilead’s Experimental HIV Treatment Matching the Efficacy…
Foster City, California — Gilead Sciences has reported that its experimental HIV treatment has met the primary goal…
Is the White House (Trump) Expanding Its Drug…
Washington, D.C. — The U.S. administration has announced a new set of agreements with nine pharmaceutical companies to…
Is Sanofi Strengthening Its Alzheimer’s Pipeline with a…
Paris – Sanofi, the global pharmaceutical company, has announced a strategic collaboration with South Korea-based biotech ADEL to…
Could Roche’s Giredestrant Become the New Standard for…
Basel, Switzerland – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive results from the Phase III lidERA…
Could GSK’s Twice-Yearly Asthma Drug Change Long-Term Treatment…
United States GlaxoSmithKline (GSK) announced today that the U.S. Food and Drug Administration (FDA) has approved its new…
Trending Posts
Latest Stories
Will Sanofi’s 2025 Earnings Cement Dupixent’s Leadership—and Its Next Growth Wave in Atopic Dermatitis?
Late January 2026 | Full-Year 2025 Earnings Preview | Immunology & Dermatology Focus Sanofi is…
Can AbbVie’s 2025 Earnings Prove Its Post-Humira Portfolio Is Built for the Next Decade?
Late January 2026 | Full-Year 2025 Earnings Preview | Biopharma Growth Strategy AbbVie is set…
Will Johnson & Johnson’s 2025 Earnings Reinforce Confidence in Its Pharma-Led Growth Engine?
Late January 2026 | Full-Year 2025 Earnings Preview | Diversified Pharma Outlook Johnson & Johnson…
Can Pfizer’s 2025 Earnings Reignite Confidence in Its Post-COVID Portfolio and Late-Stage Pipeline?
Late January 2026 | Full-Year 2025 Earnings Preview | Big Pharma Strategy Reset Pfizer is…
Gallery
